XML 12 R4.htm IDEA: XBRL DOCUMENT  v2.3.0.11
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
 3 Months Ended
Jul. 31, 2011
Jul. 31, 2010
Operating revenue:    
Personalized oncology solutions $ 601,000 $ 1,109,000
Translational oncology solutions 1,033,000 491,000
Total operating revenue 1,634,000 1,600,000
Costs and operating expenses:    
Cost of personalized oncology solutions 483,000 324,000
Cost of translational oncology solutions 419,000 222,000
Research and development 541,000 919,000
Sales and marketing 688,000 134,000
General and administrative 1,717,000 604,000
Total costs and operating expenses 3,848,000 2,203,000
Loss from operations (2,214,000) (603,000)
Other income (expense):    
Change in fair value of warrant liability 177,000 0
Other income 0 12,000
Total other income 177,000 12,000
Loss before provision for income taxes (2,037,000) (591,000)
Provision for income taxes 0 0
Net loss (2,037,000) (591,000)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share) $ (0.04) $ (0.02)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares) $ 46,420,000 $ 33,774,000